Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer

dc.date.accessioned2020-03-11T20:32:42Z
dc.date.accessioned2022-10-18T22:54:31Z
dc.date.available2020-03-11T20:32:42Z
dc.date.available2022-10-18T22:54:31Z
dc.date.created2020-03-11T20:32:42Z
dc.date.issued2016
dc.identifierhttp://hdl.handle.net/10533/239807
dc.identifier15130011
dc.identifierWOS:000367009500006
dc.identifierno scielo
dc.identifiereid=2-s2.0-84952664963
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4471146
dc.description.abstractCurrent strategies for brain diseases are mostly symptomatic and noncurative. Nanotechnology has the potential to facilitate the transport of drugs across the blood-brain barrier and to enhance their pharmacokinetic profile. However, to reach clinical app
dc.languageeng
dc.relationhttps://doi.org/10.2217/nnm.15.189
dc.relation10.2217/nnm.15.189
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.titleNanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer
dc.typeArticulo


Este ítem pertenece a la siguiente institución